Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperimmune Plasma in Severe COVID-19
NCT04385043Phase 3Unknown
- Sponsor
- University of Magna Graecia
- Start
- May 2020
- Primary completion
- Oct 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Magna Graecia. Primary endpoint: Decrease in mortality at 30 days. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04385043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385043.